AEON Biopharma, Inc. (AEON) Revenue History
Annual and quarterly revenue from 2019 to present
AEON Revenue Over Time (2019–2025)
AEON Revenue Growth History
0 of 2 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- -25.0%
- FY2021 revenue growth
- -100.0%
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
AEON Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 13, 2026, AEON Biopharma, Inc. (AEON) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
AEON's historical revenue data shows various trends over time. AEON Biopharma, Inc.'s highest annual revenue of $3.4 million was recorded in 2019.
Peer Comparison
Compared to Healthcare sector peers — including ABBV (+8.6% YoY), and ALNY (+82.6% YoY). Compare AEON vs ABBV →
AEON Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 AEONCurrent | $0 | - | - | - | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% |
AEON Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-12,803,000 | - |
| 2024 | $0 | - | $0 | - | $73.0M | - |
| 2023 | $0 | - | $0 | - | $-348,086,000 | - |
| 2022 | $0 | - | $0 | - | $-48,429,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-65,847,000 | - |
| 2020 | $2.5M | -25.0% | $2.5M | 100.0% | $-16,388,000 | -650.8% |
| 2019 | $3.4M | - | $3.4M | 100.0% | $-53,966,000 | -1607.6% |
What if you invested $1,000 in AEON back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in AEON be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AEON Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAEON vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowAEON — Frequently Asked Questions
Quick answers to the most common questions about buying AEON stock.
Is AEON's revenue growth accelerating or slowing?
AEON TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is AEON's revenue history from 2019 to 2026?
AEON Biopharma, Inc. (AEON) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is AEON's long-term revenue growth rate (CAGR)?
AEON Biopharma, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for AEON.
Why does AEON's quarterly revenue fluctuate?
AEON quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. AEON Biopharma, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is AEON's revenue distributed by segment?
AEON reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does AEON's revenue compare to industry peers?
AEON Biopharma, Inc. (AEON) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.